• Explore /
  • Poster
  • / Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) –pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial.

Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) –pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial.

Abstract Video & Slides Poster

Authors

Timothy Larson

Timothy Larson

Minnesota Oncology Hematology P.A., Minneapolis, MN

Timothy Larson , Robert M. Jotte , Ahmed Mohammed Fouad Abdelaziz , Kartik Konduri , Donald A. Richards , Michael W. Meshad , Govardhanan Nagaiah , Alexander I. Spira , Pankaj Khandelwal , Ilana Lorber , Tal Hetzroni Kedem , Marcel Rozencweig , Scott Z. Fields

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04880863

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 8615)

DOI

10.1200/JCO.2024.42.16_suppl.8615

Abstract #

8615

Poster Bd #

479

Abstract Disclosures

Similar Posters

First Author: Yuangyuan Zhao

First Author: Neil E. Faulkner

First Author: Jessica Jiyeong Lin

First Author: Scott T. Tagawa